Gilead Sciences submits application for HIV regimen to FDA
Gilead Sciences, Inc. said it submitted a new drug application to the U.S. Food and Drug Administration (FDA) on July 1 for an investigational, once-a-day single-tablet regimen for the treatment of HIV-1 infection in patients ages 12 and older. Read More »